Results 231 to 240 of about 23,377 (288)

A case of recurrent fixed drug eruption triggered by a hormonal intrauterine device. [PDF]

JAAD Case Rep
Awad N, Fontaine D, Schiele K, Regmi A, Sriharan A, Fragoso NM.   +5 more
europepmc   +1 more source

Dermatological Adverse Events Associated With Lapatinib Treatment in Dogs With Urothelial Carcinoma: A Retrospective Study

Veterinary Dermatology, EarlyView.
Lapatinib is widely used in human oncology; however, dermatological adverse events (DAEs) are common and have been correlated with treatment efficacy. In veterinary medicine, lapatinib use in combination with piroxicam has been shown to be effective in treating canine urothelial carcinoma (UC); however, the incidence and prognostic significance of DAEs
Kosuke Horita, Tomohiro Yonezawa, Yasuyuki Momoi, Shingo Maeda   +3 more
wiley   +1 more source

A critical appraisal and questions on the immunological evolution of mogamulizumab-induced drug eruption into cutaneous adult T-cell leukemia/lymphoma infiltration. [PDF]

JAAD Case Rep
Aphale P, Shekhar H, Dokania S.
europepmc   +1 more source

Concurrent Hashimoto's Encephalopathy and Papillary Thyroid Carcinoma: A Case Report

Clinical and Experimental Neuroimmunology, Volume 17, Issue 3, August 2026.
ABSTRACT Background Hashimoto's encephalopathy (HE) is a rare steroid‐responsive autoimmune syndrome. Although HE is associated with anti‐thyroid antibodies, its concurrence with malignant thyroid tumors has rarely been described and its clinical implications remain poorly understood.
Ryo Hara, Toshiyuki Kakumoto, Anna Suzuki, Satoshi Yamashita, Takayoshi Niwa, Kanako Hayashi, Arisa Morizono, Ayaka Sato, Masahiko Tanabe, Noritaka Kudo, Masashi Hamada, Wataru Satake, Tatsushi Toda   +12 more
wiley   +1 more source

Fluoroquinolone-induced generalised fixed drug eruption: a rare clinical image. [PDF]

Pan Afr Med J
Bollineni S, Aurangabadkar G.
europepmc   +1 more source

Cutaneous Adverse Drug Reactions Associated With BRAF and MEK Inhibitors: A Real‐World Analysis of WHO Pharmacovigilance Data

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 274-285, July 2026.
BRAF inhibitors and MEK inhibitors (MEKi) have reshaped the treatment of BRAFV600‐mutant malignancies; however, cutaneous adverse drug reactions (ADRs) remain a frequent and clinically impactful toxicity. Although clinical trials provide insight into their safety profiles, real‐world data on dermatologic ADRs are limited.
Natalia Sauer, Piotr Giedziun, Jacek Calik, Anna Wiela‐Hojeńska   +3 more
wiley   +1 more source

Successful Treatment of Ustekinumab-Associated Lichenoid Drug Eruption with Upadacitinib: A Case Report. [PDF]

Clin Cosmet Investig Dermatol
Xia M, Zhang J, Tian X, Chen Z, Liang J, Liu Y.   +5 more
europepmc   +1 more source

Vitamin‐Responsive Disorders: From Molecular Basis to Clinical Presentation and Therapy

Journal of Inherited Metabolic Disease, Volume 49, Issue 4, July 2026.
ABSTRACT Vitamin‐dependent cofactors are essential for numerous metabolic reactions, and defects affecting their uptake, conversion, utilisation, or regeneration constitute a heterogeneous group of inherited metabolic disorders (IMDs). Although dietary vitamin intake is sufficient to sustain coenzyme synthesis in healthy individuals, it is insufficient
Cécile Acquaviva, Yann Nadjar, Manuel Schiff, Christine Vianey‐Saban, Alain Fouilhoux, Jean‐François Benoist   +5 more
wiley   +1 more source

Biopsy Confirmed Skin Drug Eruption in Setting of Ticagrelor Use. [PDF]

J Investig Med High Impact Case Rep
Steinwehr DE, Gales JM, de Leeuw AR, Anderson DS, Cunningham CR, Smith AAH.   +5 more
europepmc   +1 more source